#Singapore #Philadelphia #Nuevocor #Dr. Monica Shah #LMNA DCM

Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer

Nuevocor, a cutting-edge clinical-stage biotechnology company, is making headlines with the recent appointment of Dr. Monica Shah as their Chief Medical Officer. Known for developing groundbreaking therapies aimed at treating severe cardiomyopathies, Nuevocor is poised to take significant strides in its clinical endeavors with Dr. Shah's extensive expertise.

Dr. Shah, a board-certified cardiologist specializing in heart failure and transplant medicine, brings over 20 years of experience in cardiovascular healthcare and drug development across various esteemed platforms, including academia and the National Institutes of Health (NIH). Her most recent position was with CTI Clinical Trial Consulting, a specialty contract research organization (CRO), where she was instrumental in driving the medical strategy across a range of complex clinical trials involving rare diseases, gene therapies, and cardiovascular indications.

Before her role at CTI, Dr. Shah served as the Senior Vice President and Global Program Head for AAV at Rocket Pharmaceuticals. In this capacity, she launched pivotal clinical programs focused on gene therapy for cardiovascular conditions. Her background also includes a notable tenure at IQVIA, where she led the Cell and Gene Therapy initiatives, collaborating with various sponsors to guide programs from early development stages through to commercialization. Additionally, her extensive experience at NIH included roles as the Deputy Chief of Heart Failure and Arrhythmias and as the Director of the Trial Innovation Network.

With a wealth of experience, Dr. Shah is stepping into her role at an exciting juncture for Nuevocor as they prepare to commence their first-in-human clinical trial of NVC-001, aimed at patients with LMNA-associated dilated cardiomyopathy (DCM). This particular condition is one of the most aggressive forms of genetic heart disease, which makes Dr. Shah's leadership crucial as the company seeks to introduce effective therapies for patients facing limited options.

Dr. Al Gianchetti, CEO of Nuevocor, expressed confidence in Dr. Shah's capabilities: "Monica is an exceptional clinical development leader who brings precisely the right combination of cardiovascular expertise, gene therapy execution, and regulatory experience to Nuevocor. As we prepare to initiate the first-in-human clinical trial of NVC-001 in LMNA DCM, we look forward to her leadership in bringing novel therapeutics to patients with serious unmet medical needs."

LMNA DCM is notorious for its fast progression towards end-stage heart failure and has been widely regarded as a devastating disease with scarce treatment options. Dr. Shah commented on the significance of Nuevocor's innovative approach: "Nuevocor's mechanobiology-driven strategy presents a genuinely differentiated opportunity to intervene at the biological level of disease. I am thrilled to be part of this team at such a pivotal moment and am eager to guide NVC-001 into clinical applications, translating our unique platform's potential into meaningful patient outcomes."

Understanding NVC-001

NVC-001 is heralded as a first-in-class gene therapy directed at LMNA-related dilated cardiomyopathy (LMNA DCM). This condition is characterized by rapid progression towards severe heart failure and malignant ventricular arrhythmias that heighten the risk of sudden cardiac death. Notably, NVC-001 is designed to reduce the forces affecting the nucleus, thus restoring the integrity of the nuclear envelope—a critical aspect of LMNA DCM pathology.

Preclinical studies have showcased significant benefits of NVC-001, including improved survival rates and enhanced cardiac function. Following a successful preclinical phase, Nuevocor intends to kickstart their first-in-human clinical trial sometime in 2026.

About Nuevocor

Headquartered in Singapore, Nuevocor is dedicated to developing innovative treatments for genetic cardiomyopathies arising from flawed mechanobiology. The company recently secured $50 million in financing from notable investors including Kurma Partners and Boehringer Ingelheim Venture Fund. The proprietary PrOSIA mechanism enables Nuevocor to transcend conventional gene replacement therapies and tackle shared disease pathways in multiple cardiomyopathies, addressing the root causes rather than merely the symptoms.

Nuevocor stands as a pioneer in addressing genetic cardiomyopathies that are unresponsive to traditional therapy methods, representing a beacon of hope for patients who have been left without effective treatment options. Visit Nuevocor’s website to learn more about their groundbreaking work.